This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Nephrology & Cardiology Products
Kerendia®▼ (finerenone)
Product Page
PP-KER-GB-0752, January 2025
Oncology Products
NUBEQA® (darolutamide)
In nmCRPC and mHSPC
PP-NUB-GB-2217, March 2025
Xofigo®▼ (radium-223 dichloride)
In mCRPC
PP-XOF-GB-0648, April 2025
Women's Health Products
Qlaira® (Estradiol valerate/dienogest)
PP-PF-WHC-IUS-GB-0107, March 2025
Jaydess® ▼ (13.5mg levonorgestrel)
PP-PF-WHC-IUS-GB-0106, March 2025
Mirena® (52mg levonorgestrel)
PP-PF-WHC-IUS-GB-0024, May 2024
Kyleena® 19.5mg levonorgestrel
PP-PF-WHC-IUS-GB-0018, February 2024
Ophthalmology
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025